Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
The Journal of Biological Chemistry|February 26, 2010
p35 is required for CDK5 activation in cellular senescenceDaqin Mao, Philip W Hinds
Breast Cancer Research and Treatment|September 12, 2020
Treatment interruption and discontinuation of hormonal therapy in hormone receptor-positive breast cancer patientsDaqin Mao, Hilal Hachem, Hong Chang, et al.
Molecular Therapy. Advances|May 15, 2026
Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignanciesShruti Sanjay Salunkhe, Jenny Nater, Colleen Schweitzer, et al.
Clinical Pharmacokinetics|September 6, 2024
Investigating the Influence of Covariates on Axicabtagene Ciloleucel (axi-cel) Kinetics in Patients with Non-Hodgkin's LymphomaMagali Chartier, Simone Filosto, Thomas Peyret, et al.
Frontiers in Oncology|March 14, 2025
Tumor gene expression signatures associated with outcome in large B-cell lymphoma treated with CD19-directed CAR T-cell therapy (axicabtagene ciloleucel)Yuan Tian, Justin Budka, Frederick L Locke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2026
Phase 1 Study of KITE-222, an Autologous CLL-1-directed CAR T-cell Therapy in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNaval Daver, James S Blachly, Armin Ghobadi, et al.
Cancer Research|January 22, 2009
A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesisMiaofen G Hu, Amit Deshpande, Miriam Enos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 13, 2025
Axicabtagene Ciloleucel in Combination With Atezolizumab in Patients With Refractory Diffuse Large B-cell Lymphoma: The Phase 1/2 ZUMA-6 TrialCaron A Jacobson, Jason R Westin, David B Miklos, et al.
Clinical Breast Cancer|August 24, 2019
Timeliness of Treatment Initiation in Newly Diagnosed Patients With Breast CancerJinghui Dong, Kimberly S Esham, Lauren Boehm, et al.
Frontiers in Oncology|June 10, 2026
A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)Kedar Kirtane, Jiaxin Niu, George Blumenschein, et al.
Pageof 2